Edition:
India

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

14.20USD
24 Nov 2017
Change (% chg)

$-0.45 (-3.07%)
Prev Close
$14.65
Open
$14.55
Day's High
$14.65
Day's Low
$14.10
Volume
63,449
Avg. Vol
216,634
52-wk High
$36.80
52-wk Low
$11.93

Chart for

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $661.66
Shares Outstanding(Mil.): 35.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31

* Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights

02 Nov 2017

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

31 Aug 2017

BRIEF-Amag Pharmaceuticals Q2 loss per share $0.40

* Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update

03 Aug 2017

BRIEF-Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia

* Amag completes Feraheme® (ferumoxytol) FDA submission for the treatment of all adult patients with iron deficiency anemia

03 Aug 2017

BRIEF-Amag Pharmaceuticals announces commercial availability of Intrarosa (prasterone) at U.S. pharmacies

* Says announces commercial availability of intrarosa (prasterone) at U.S. pharmacies

24 Jul 2017

BRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena

* Amag announces U.S. FDA filing acceptance of supplemental new drug application for makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector

26 Jun 2017

Earnings vs. Estimates